Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy

Chagas disease is a parasitic infection caused by the intracellular protozoan Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC) is the most severe manifestation of the disease, developed by approximately 20-40% of patients and characterized by occurrence of arrhythmias, heart failure and death....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emanuelle de Souza Santos, Dahara Keyse Carvalho Silva, Bruna Padilha Zurita Claro dos Reis, Breno Cardim Barreto, Carine Machado Azevedo Cardoso, Ricardo Ribeiro dos Santos, Cássio Santana Meira, Milena Botelho Pereira Soares
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Chagas disease Trypanosoma cruzi cardiomyopathy immunomodulation immunotherapy Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/f72f181d972a4d3c8667e4a95c95e2da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f72f181d972a4d3c8667e4a95c95e2da
record_format	dspace
spelling	oai:doaj.org-article:f72f181d972a4d3c8667e4a95c95e2da2021-11-12T05:43:09ZImmunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy2235-298810.3389/fcimb.2021.765879https://doaj.org/article/f72f181d972a4d3c8667e4a95c95e2da2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcimb.2021.765879/fullhttps://doaj.org/toc/2235-2988Chagas disease is a parasitic infection caused by the intracellular protozoan Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC) is the most severe manifestation of the disease, developed by approximately 20-40% of patients and characterized by occurrence of arrhythmias, heart failure and death. Despite having more than 100 years of discovery, Chagas disease remains without an effective treatment, especially for patients with CCC. Since the pathogenesis of CCC depends on a parasite-driven systemic inflammatory profile that leads to cardiac tissue damage, the use of immunomodulators has become a rational alternative for the treatment of CCC. In this context, different classes of drugs, cell therapies with dendritic cells or stem cells and gene therapy have shown potential to modulate systemic inflammation and myocarditis in CCC models. Based on that, the present review provides an overview of current reports regarding the use of immunomodulatory agents in treatment of CCC, bringing the challenges and future directions in this field.Emanuelle de Souza SantosDahara Keyse Carvalho SilvaBruna Padilha Zurita Claro dos ReisBreno Cardim BarretoCarine Machado Azevedo CardosoRicardo Ribeiro dos SantosRicardo Ribeiro dos SantosCássio Santana MeiraCássio Santana MeiraMilena Botelho Pereira SoaresMilena Botelho Pereira SoaresFrontiers Media S.A.articleChagas diseaseTrypanosoma cruzicardiomyopathyimmunomodulationimmunotherapyMicrobiologyQR1-502ENFrontiers in Cellular and Infection Microbiology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chagas disease Trypanosoma cruzi cardiomyopathy immunomodulation immunotherapy Microbiology QR1-502
spellingShingle	Chagas disease Trypanosoma cruzi cardiomyopathy immunomodulation immunotherapy Microbiology QR1-502 Emanuelle de Souza Santos Dahara Keyse Carvalho Silva Bruna Padilha Zurita Claro dos Reis Breno Cardim Barreto Carine Machado Azevedo Cardoso Ricardo Ribeiro dos Santos Ricardo Ribeiro dos Santos Cássio Santana Meira Cássio Santana Meira Milena Botelho Pereira Soares Milena Botelho Pereira Soares Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy
description	Chagas disease is a parasitic infection caused by the intracellular protozoan Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC) is the most severe manifestation of the disease, developed by approximately 20-40% of patients and characterized by occurrence of arrhythmias, heart failure and death. Despite having more than 100 years of discovery, Chagas disease remains without an effective treatment, especially for patients with CCC. Since the pathogenesis of CCC depends on a parasite-driven systemic inflammatory profile that leads to cardiac tissue damage, the use of immunomodulators has become a rational alternative for the treatment of CCC. In this context, different classes of drugs, cell therapies with dendritic cells or stem cells and gene therapy have shown potential to modulate systemic inflammation and myocarditis in CCC models. Based on that, the present review provides an overview of current reports regarding the use of immunomodulatory agents in treatment of CCC, bringing the challenges and future directions in this field.
format	article
author	Emanuelle de Souza Santos Dahara Keyse Carvalho Silva Bruna Padilha Zurita Claro dos Reis Breno Cardim Barreto Carine Machado Azevedo Cardoso Ricardo Ribeiro dos Santos Ricardo Ribeiro dos Santos Cássio Santana Meira Cássio Santana Meira Milena Botelho Pereira Soares Milena Botelho Pereira Soares
author_facet	Emanuelle de Souza Santos Dahara Keyse Carvalho Silva Bruna Padilha Zurita Claro dos Reis Breno Cardim Barreto Carine Machado Azevedo Cardoso Ricardo Ribeiro dos Santos Ricardo Ribeiro dos Santos Cássio Santana Meira Cássio Santana Meira Milena Botelho Pereira Soares Milena Botelho Pereira Soares
author_sort	Emanuelle de Souza Santos
title	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy
title_short	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy
title_full	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy
title_fullStr	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy
title_full_unstemmed	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy
title_sort	immunomodulation for the treatment of chronic chagas disease cardiomyopathy: a new approach to an old enemy
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/f72f181d972a4d3c8667e4a95c95e2da
work_keys_str_mv	AT emanuelledesouzasantos immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT daharakeysecarvalhosilva immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT brunapadilhazuritaclarodosreis immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT brenocardimbarreto immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT carinemachadoazevedocardoso immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT ricardoribeirodossantos immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT ricardoribeirodossantos immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT cassiosantanameira immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT cassiosantanameira immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT milenabotelhopereirasoares immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy AT milenabotelhopereirasoares immunomodulationforthetreatmentofchronicchagasdiseasecardiomyopathyanewapproachtoanoldenemy
_version_	1718431205504843776

Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy

Ejemplares similares